Opyl hosted a thought-provoking webinar, The Strategic Advantage of Expert CRO Partnerships, featuring Associate Professor Tina Soulis from Alithia Life Sciences and Dr Minh-Thu Cao Xuan from Opyl, with Bernice Averion moderating. The session explored how AI-powered analytics and operational expertise are transforming clinical trial design, execution, and success rates.
Dr Minh-Thu Cao Xuan presented how Opyl’s AI-driven tool, TrialKey, is redefining clinical trial optimisation. TrialKey analyses over 1,300 variables in trial protocols and runs 100,000 simulations to identify the key factors influencing trial success. This allows sponsors to refine trial protocols by testing variables such as trial location, enrolment numbers, and study duration. It also helps optimise site selection by ranking sites based on historical performance and improves patient recruitment with smarter inclusion and exclusion criteria that enhance enrolment efficiency without compromising data quality. TrialKey further strengthens RFPs by providing predictive success scores and competitive benchmarking, helping sponsors secure more projects.
Associate Professor Tina Soulis highlighted how Alithia Life Sciences brings decades of operational expertise to complement AI-driven insights. With deep industry knowledge, Alithia ensures that trial strategies are practical, regulatory-compliant, and aligned with market needs. Combining AI-driven predictive analytics with real-world CRO experience enables sponsors to move through clinical phases more efficiently, reducing time and costs while improving trial outcomes.
The discussion also touched on emerging trends in clinical trials. Decentralised trials are improving accessibility and patient retention by allowing remote participation. AI and machine learning continue to enhance trial design and outcome prediction, while real-world data and real-world evidence are playing a greater role in regulatory decisions. The use of wearable devices and digital health tools is streamlining data collection, and the rise of precision medicine and biomarker-driven trials is supporting the development of more targeted and effective therapies.
By combining AI-powered insights with CRO expertise, TrialKey and Alithia Life Sciences offer a strategic advantage for sponsors looking to optimise trial design, reduce costs, and accelerate market entry. The insights shared in this webinar reinforce how advanced analytics and industry experience together create a smarter, more efficient clinical trial process.
